MedTrace Logo

Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus

NCT03014479 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2023-12-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the reduction in treatment burden during 12 weeks of trelagliptin administration in patients with type 2 diabetes on diet and exercise therapy only.

Conditions

Interventions

DRUG

Trelagliptin

Trelagliptin 100 mg or 50 mg

DRUG

Daily DPP-4 inhibitor

Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-18
Primary Completion
2017-10-21
Completion
2017-10-21

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03014479 on ClinicalTrials.gov